Pamorelin LA 3.75mg Injection contains an active component as Triptorelin.  It is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) analogs. It is primarily used in the field of reproductive medicine for the treatment of various conditions related to hormonal imbalance. One of the most common use is in treating certain hormone-dependent conditions such as prostate cancer, breast cancer, and endometriosis. In prostate cancer, for example, this medication is used to lower the levels of testosterone, which can help slow down the growth of cancer cells.

Pamorelin LA 3.75mg Injection should not be used in individuals who have a known hypersensitivity or allergic reaction to the medication or any of its components. The safety and effectiveness of this medication have not been established in children, so a healthcare professional will carefully consider and monitor its use in this population. Pamorelin LA 3.75mg Injection may have cardiovascular effects, including an increased risk of heart attack or stroke. It should be used cautiously in individuals with a history of cardiovascular disease or those at increased risk.

Pamorelin LA 3.75mg Injection is used to treat the following:

• Prostate cancer in men
• Early onset puberty in children 2 years of age and older (precocious puberty)

Pamorelin LA 3.75mg Injection exerts its therapeutic effect by suppressing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through its action on the pituitary gland. This suppression leads to a decrease in the production of sex hormones, such as testosterone and estrogen. By reducing the levels of these hormones, This medication is beneficial in treating hormone-dependent conditions such as prostate cancer, breast cancer, and endometriosis. 

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Pamorelin LA 3.75mg Injection, reducing effectiveness by causing undesirable side effects.

• Store at room temperature, between 20°C to 25°C (68°F to 77°F).
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep away from children and pets.

Pamorelin LA 3.75mg Injection is typically administered via injection, either subcutaneously (under the skin) or intramuscularly (into the muscle). The specific dosing and frequency of administration will depend on the individual's condition being treated and their response to the medication. It is important to follow the healthcare professional's instructions regarding the administration technique and schedule.

Pamorelin LA 3.75mg Injection cause some side effects like all medications, although not everyone will experience them. 

Serious:

• Swallowing or breathing trouble
• Increased lymphocyte count in the blood
• Swelling of lips, tongue or throat

Common:

• Hot flushes
• Weakness
• Excessive sweating
• Back pain
• Impotence
• Nausea
• Dry mouth
• Pain, bruising, redness at the injection site
• High blood pressure
• Weight gain
• Dizziness
• Headache

It is important to use of Pamorelin LA 3.75mg Injection with caution and adhere to the following precautions to ensure its safe and effective use. First, always use under the supervision and guidance of a healthcare professional who can monitor your progress and make necessary adjustments to your treatment plan. Inform your healthcare professional about any existing medical conditions, including liver impairment, lung conditions, or pregnancy or breastfeeding, as it may have specific considerations or contraindications in these cases. Adhere to the prescribed dosage and administration instructions, and do not adjust the dose without consulting your healthcare professional.

Be aware of possible side effects, such as hot flashes, mood changes, or fatigue, and promptly report any concerning or persistent symptoms to your healthcare professional. Regular follow-up appointments and monitoring are essential to assess your response to this medication and address any concerns or issues that may arise. By taking these precautions and maintaining open communication with your healthcare professional, you can maximize the benefits of this medication while minimizing potential risks.

1. Ipsen Limited, Electronic Medicines Compendium (EMC), [Revised on Jun 2017] [Accessed on 18th July 2023],  https://www.medicines.org.uk/emc/files/pil.5906.pdf
2. Allergan, US Food & Drug Administration, [Revised on Dec 2018] [Accessed on 18th July 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf
3. Claudine Isaacs, Anton Wellstein, and Anna T. Riegel, Hormones and Related Agents in the Therapy of Cancer, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1237-1247.